BioMarin Pharmaceutical Names Ian Clark as Chair
Published on 04/21/2026 at 05:35 pm EDT
MT Newswires
Share
Share
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.95 USD | +0.74% |
|
-1.44% | -5.86% |
| May. 20 | Health Care Up as Biotech Rallies on Risk Appetite -- Health Care Roundup | DJ |
| May. 20 | BioMarin's drug shows significant growth gains in children in late-stage trial | RE |
![Randy Meier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Richard A. Meier is currently Co-Managing Director at Intersect ENT International GmbH and Intersect ENT GmbH, Member of the Supervisory Board at Syntellix AG, and Partner at Atlas Rock Co. Former roles include President, Chief Executive Officer & Director at Rockley Photonics Holdings Ltd. (2022–2023); Chairman at BioMarin Pharmaceutical, Inc. (2006–2026); Independent Director at STAAR Surgical Co. (2011–2016); Principal at Greyhound Lines, Inc., Australian Capital Equity Pty Ltd., Manufacturers Hanover Corp., and Salomon Smith Barney, Inc.; Chief Financial Officer & Executive Vice President at Bausch Health Americas, Inc. (1999); CFO, Executive VP & President-International at Accendra Health, Inc. (2015–2018); Chief Financial Officer & Executive Vice President at Teleflex, Inc. (2010–2011); Senior Vice President at Schroder & Co., Inc. (1996–1998); President & Chief Operating Officer at Advanced Medical Optics, Inc. (2007–2009); and Chief Financial Officer & Executive Vice President at Intersect ENT, Inc. (2019–2022).
Education includes undergraduate studies at Princeton University.
Employees
3,221
Sector
Pharmaceuticals
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
BBB
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
55.95USD
Average target price
87.85USD
Spread / Average Target
+57.01%
Quarterly revenue - Rate of surprise
- Stock Market
- Stock Market News
- BioMarin Pharmaceutical Names Ian Clark as Chair
Select your edition
All financial news and data tailored to specific country editions
